ilmscore | Prediction Details
"The phase-out of Novo Nodex has opened up opportunities worth $450 crore in India and $157 million in emerging markets. In which only three players including work hard can benefit."
By Groww | January 11, 2026 | Pending
From video
3 stocks with business turnaround from loss to profits 00:11:54 - 00:12:10
Interpreted Prediction
Wockhardt, as one of only three players, is poised to benefit from new human insulin market opportunities in India (worth Rs 450 crore) and emerging markets (worth $157 million), following the phase-out of Novo Nordisk's 'Novo Nodex'.

Prediction Details

Topic
Wockhardt Limited

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.